The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | The advent of CAR-T therapy for CLL and emerging promising combinations
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, St. Vincent’s Hospital, University of Melbourne, Melbourne, Australia, discusses recent advances in CAR-T therapy for chronic lymphocytic leukemia (CLL), commenting on the promise of combining CAR-Ts with ibrutinib to improve T-cell function and reduce toxicity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Beigene: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; LOXO: Honoraria; AstraZeneca: Honoraria; Janssen: Honoraria, Research Funding.
